Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Age-Related Macular Degeneration Market Size Changed, over the years?
The market size for age-related macular degeneration has seen significant growth in the past few years. An increase from $9.96 billion in 2024 to $10.7 billion in 2025 is expected, with a compound annual growth rate (CAGR) of 7.5%. This growth during the historical period is a result of factors such as ageing population demographics, alterations in lifestyles and environment, genetic susceptibility, heightened awareness and early diagnosis, and the progression in diagnostic methods.
How Much Will the Age-Related Macular Degeneration Market Be Worth in 2029?
The market size for age-related macular degeneration is projected to significantly expand in the upcoming years, reaching an estimated $14.38 billion in 2029 with a compound annual growth rate (CAGR) of 7.7%. The predicted growth within this forecast period is largely due to advancements in genetic and biomarker research, emergent therapeutic methods, the advent of telemedicine and remote patient monitoring, and an uptick in patient advocacy and education. Notable trends within this forecast period encompass personalized medicine techniques, advances in retinal imaging technology, the development of sustained drug delivery systems, clinical testing for novel therapies, and increased emphasis on partnerships for research and development.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10845&type=smp
Which is the Largest Company in the Age-Related Macular Degeneration Market?
Major companies operating in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.
What Are the Main Market Drivers in the Age-Related Macular Degeneration Industry?
The age-related macular degeneration (AMD) market is projected to grow due to the increasing prevalence of this condition. AMD is a progressive vision impairment, affecting the macula which is a small portion of the retina that is critical for central vision. Treatments for AMD aim to reduce the disease’s intensity and assist those struggling with retinal disorders. For example, in February 2023, Optimaxa, a prominent UK-based laser eye treatment provider, reported that AMD had afflicted 196 million people across the globe and projected this figure to rise to 288 million by 2040, totaling 8.7 percent of the global population. Thus, the escalating incidence of AMD is contributing to the expansion of the age-related macular degeneration market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=10845&type=smp
How Is the Age-Related Macular Degeneration Market Segments Structured?
The age-related macular degeneration market covered in this report is segmented –
1) By Type: Wet Age-Related Macular Degeneration (AMD), Dry Age-Related Macular Degeneration (AMD)
2) By Drug: Eylea, Lucentis, Avastin, Other Products
3) By Route Of Administration: Intravenous, Intravitreal
4) By Distribution Channel: Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy
Subsegments:
1) By Wet Age-Related Macular Degeneration (AMD): Anti-VEGF Injections, Photodynamic Therapy, Laser Surgery
2) By Dry Age-Related Macular Degeneration (AMD): Nutritional Supplements, Low Vision Aids, Therapies For Geographic Atrophy
What Strategic Trends Are Transforming the Age-Related Macular Degeneration Market?
In an attempt to innovate treatments for reduced frequency, leading companies in the age-related macular degeneration (AMD) market have turned to the development of bispecific antibodies. These are specially engineered antibodies that can simultaneously bind to two distinct antigens. Case in point, Chugai Pharmaceutical Co., Ltd., a pharmaceutical enterprise based in Japan, pioneered the introduction of Vabysmo intravitreal injection 120 mg/mL in May 2022. This bispecific antibody is specifically formulated to treat eye diseases such as AMD and diabetic macular edema (DME). The therapy works through simultaneously targeting two fundamental pathways: angiopoietin-2 (Ang-2), associated with irregular blood vessel growth and inflammation, and Vascular Endothelial Growth Factor-A (VEGF-A), which is instrumental in new blood vessel formation and can result in vision impairment. Vabysmo’s unique advantage is its broadened dosing intervals, which allows for administration every 16 weeks, thereby improving patient comfort and adherence. Its double-action strategy signifies a considerable advancement in eye treatments, effectively addressing the pressing need for dependable therapies in retinal disorders.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Age-Related Macular Degeneration Market?
North America was the largest region in the global age-related macular degeneration market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10845
This Report Delivers Insight On:
1. How big is the age-related macular degeneration market, and how is it changing globally?
2. Who are the major companies in the age-related macular degeneration market, and how are they performing?
3. What are the key opportunities and risks in the age-related macular degeneration market right now?
4. Which products or customer segments are growing the most in the age-related macular degeneration market?
5. What factors are helping or slowing down the growth of the age-related macular degeneration market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
